(S1 (S (PP (IN Of) (NP (NN note))) (, ,) (ADVP (RB however)) (, ,) (NP (NP (NN GALNT2) (NN drug1)) (-LRB- -LRB-) (VP (ADVP (RB previously)) (VBN associated) (PP (IN with) (NP (NP (NP (JJ high-density) (NN lipoprotein) (NN cholesterol)) (NNS levels)) (PP (IN in) (NP (NN EA)))))) (-RRB- -RRB-)) (VP (VBD had) (NP (JJ multiple) (ADJP (RB potentially) (JJ novel)) (NN PheWAS) (NNS associations)) (, ,) (PP (PP (IN with) (NP (NP (NN hypertension) (JJ related) (NNS phenotypes)) (PP (IN in) (NP (NN AA))))) (CC and) (PP (IN with) (NP (NP (NP (NN serum) (NN calcium) (NNS levels)) (CC and) (NP (NN drug2) (NNS phenotypes))) (PP (IN in) (NP (NN EA))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN majority)) (PP (IN of) (NP (DT the) (ADJP (RB potentially) (JJ novel)) (NNS results)))) (VP (VBD were) (PP (IN for) (NP (JJ single) (NN PheWAS) (NNS phenotype-classes))))) (, ,) (S (PP (IN for) (NP (NN example))) (, ,) (PP (IN for) (NP (NP (NN CDKN2A/B) (NN drug1)) (-LRB- -LRB-) (VP (ADVP (RB previously)) (VBN associated) (PP (IN with) (NP (NP (NN type) (CD 2) (NN drug2)) (PP (IN in) (NP (NN EA)))))) (-RRB- -RRB-))) (NP (DT a) (JJ PheWAS) (NN association)) (VP (VBD was) (VP (VBN identified) (PP (IN for) (NP (NP (NN hemoglobin) (NNS levels)) (PP (IN in) (NP (NN AA)))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (NN drug1) (: :) (NP (NNP C>G))) (PP (PP (IN in) (NP (NP (NN INK4) (NN locus)) (PP (IN in) (NP (JJ familial) (NN drug2) (NNS patients))))) (CC and) (PP (IN on) (NP (NP (NN lipid) (NN profile)) (PP (IN of) (NP (DT the) (NNS patients))))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN studied) (PP (IN in) (NP (NN Pakistan)))))) (. .)))
(S1 (S (S (NP (NP (DT An) (JJ epistatic) (NN interaction)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (CD 1.56)) (, ,) (NP (NN p=1.19) (NN *) (CD 10) (-LRB- -LRB-) (CD -2) (-RRB- -RRB-))) (-RRB- -RRB-)))))) (VP (VBD was) (VP (VBN found) (PP (ADVP (RB especially)) (IN in) (NP (NP (NN presence)) (PP (IN of) (NP (NP (NN drug3) (NN disease)) (PRN (-LRB- -LRB-) (NP (CD OR=2.15) (, ,) (CD p=3.12) (NN *) (CD 10) (-LRB- -LRB-) (CD -4) (-RRB- -RRB-)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (PP (IN In) (NP (NP (DT a) (JJ longitudinal) (NN study)) (PP (IN with) (NP (NP (CD 11) (NNS years)) (PP (IN of) (NP (NN follow-up))))) (PP (IN on) (NP (NP (NN survival)) (PP (IN in) (NP (DT the) (JJ oldest-old) (NN Danes))))))) (, ,) (NP (NP (QP (RB only) (CD one)) (NN SNP)) (, ,) (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN IL6)) (-RRB- -RRB-))) (, ,)) (VP (VBD was) (ADVP (NN borderline) (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN from) (NP (NN age) (CD 92))))) (PRN (-LRB- -LRB-) (NP (NNP P-corrected=0.064)) (-RRB- -RRB-)))) (. .)))
(S1 (S (NP (NP (NNS Haplotypes)) (PP (IN of) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (CC or) (NP (NP (NN drug3)) (CC and) (NP (NN drug4)))))) (VP (VBD revealed) (NP (NP (DT an) (NN association)) (PP (IN with) (NP (NP (NN drug5) (NN cancer)) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (ADJP (RB significantly) (JJR stronger)) (PP (IN in) (NP (DT the) (JJ homozygous) (NNS carriers)))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ nonsynonymous) (NN OPRM1) (NN drug1)) (VP (MD might) (VP (VB be) (NP (NP (DT a) (NN risk) (NN factor)) (PP (IN for) (NP (NP (NN drug2)) (PP (TO to) (NP (NP (NN opioids)) (CC or) (NP (NN heroin))))))) (PP (IN in) (NP (DT an) (JJ Asian) (NN population)))))) (. .)))
(S1 (S (S (NP (DT No) (NN association)) (VP (VBD was) (VP (VBN found) (PP (IN between) (NP (NP (NP (JJ drug2) (NNS phenotypes)) (PRN (-LRB- -LRB-) (NP (NP (NN incidence)) (, ,) (NP (NN intensity)) (, ,) (CC and) (NP (NN duration))) (-RRB- -RRB-))) (CC and) (NP (JJ different) (NN drug1) (NNS genotypes))))))) (. .)))
(S1 (S (NP (NP (NNS Results)) (VP (VBD revealed) (NP (NP (DT an) (NN association)) (PP (IN between) (NP (NP (NN drug1)) (CC and) (NP (NP (NN cocaine)) (CC and) (NP (NN heroin)) (NP (NN drug2)))))) (PP (IN in) (NP (NP (NNP European) (NNP Americans)) (PRN (-LRB- -LRB-) (NP (NN p=0.02)) (: ;) (S (NP (CD 95) (NN %)) (NP (NNP C.I.) (CD 0.47) (CD -LSB-0.24-0.92) (-RRB- -RSB-))) (-RRB- -RRB-))))))))
(S1 (S (S (NP (DT The) (NN 118G) (NN allele)) (VP (VBD conferred) (NP (NP (ADVP (RB 5.3-fold)) (VBN increased) (NNS odds)) (PP (IN of) (NP (NP (NN drug2)) (: /) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN p<0.05)) (-RRB- -RRB-)))))) (, ,) (SBAR (IN while) (S (NP (DT the) (NN drug1) (JJ variant) (NN allele)) (VP (VBD was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NN drug4))))))))) (: /) (NP (NN drug5))))
(S1 (S (PP (IN In) (NP (DT this) (NN meta) (NN analysis))) (, ,) (NP (PRP we)) (VP (VBD assessed) (NP (CD 10) (JJ case-control) (NNS studies)) (VP (VBD included) (NP (NP (NP (CD 7,067) (NNS cases)) (CC and) (NP (CD 9,374) (NNS controls))) (PP (IN of) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NP (NN CYP1B1) (NNS SNPs) (IN of) (NN Leu432Val)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN 432C>G))) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NP (NNP Asn453Ser)) (PRN (-LRB- -LRB-) (NP (NNP drug2) (, ,) (NNP 453A>G)) (-RRB- -RRB-))) (, ,) (NP (NP (NNP Ala119Ser)) (PRN (-LRB- -LRB-) (NP (NP (NNP drug3)) (, ,) (NP (CD 119G>T))) (-RRB- -RRB-))) (, ,) (NP (NNP Arg48Gly))) (PRN (-LRB- -LRB-) (NP (NP (CD drug4)) (, ,) (NP (NN 48C>G))) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug5))))))))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (PP (IN In) (NP (PRP$ our) (JJ human) (NN study))) (, ,) (NP (DT the) (NN A118G) (NN singlenucleotide) (NN polymorphism) (NN drug1)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2) (NN virus) (NN disease) (NN severity)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (NN 0.015)) (-RRB- -RRB-))))))) (. .))))
(S1 (S (PP (VBN Compared) (PP (TO to) (NP (NNS controls)))) (, ,) (NP (NP (NN drug3) (NNS patients)) (-LRB- -LRB-) (PP (PP (IN with)) (CC and) (PP (IN without) (NP (NN drug4)))) (-RRB- -RRB-)) (VP (VBD showed) (NP (NP (ADJP (RB significantly) (VBN increased)) (NN frequency)) (PP (IN of) (NP (NP (NP (DT the) (NN DBH)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (: :) (NP (NP (NN OR) (CD 1.73)) (: ;) (NP (NN CI) (CD 1.15-2.59)) (: ;) (NP (CD P=0.008))) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NN OPRM1) (NN risk) (NNS genotypes)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (: :) (NP (NP (NN OR) (CD 1.71)) (: ;) (NP (NN CI) (CD 1.17-2.50)) (: ;) (NP (CD P=0.006))) (-RRB- -RRB-))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (DT the) (NN drug1) (NN SNP)) (VP (MD could) (VP (VB predict) (NP (NP (JJ clinical) (NN outcome)) (PP (VBG regarding) (NP (NP (NN progression)) (PP (IN of) (NP (NP (NN drug2)) (CC and) (NP (NN disability)))) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NP (JJ low) (NN drug3)) (CC and) (NP (NN drug4))) (PP (IN after) (NP (NN drug5) (NN herniation))))))))))))))) (. .)))
(S1 (S (S (NP (JJR Earlier) (NNS studies)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP (NP (DT the) (JJ single) (NN nucleotide) (NN polymorphism)) (ADJP (JJ drug1) (PP (IN in) (NP (DT the) (NN opioid) (NN receptor) (NN mu) (CD 1) (-LRB- -LRB-) (NN OPRM1) (-RRB- -RRB-) (NN gene))))) (VP (MD may) (VP (VB affect) (NP (NN drug2))))))))) (. .)))
(S1 (S (NP (NNS Individuals)) (VP (VBD were) (VP (VBN genotyped) (PP (IN for) (NP (NP (NP (NN PCSK9) (NN R46L)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (, ,) (NP (NP (NN ABCG8) (NN D19H)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN APOE) (NNP R112C) (PRN (-LRB- -LRB-) (NP (NN drug3)) (-RRB- -RRB-)) (CC and) (NN R158C) (NN drug4) (NNS polymorphisms)))))) (, ,) (SBAR (WHNP (NP (DT all)) (WHPP (IN of) (WHNP (WDT which)))) (S (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NN drug5)))))))))
(S1 (S (S (NP (NP (JJ Male) (NNS children)) (PP (IN of) (NP (NNS alcoholics)))) (VP (VBD were) (ADJP (RBR less) (JJ likely)) (S (VP (TO to) (VP (VB be) (NP (NP (NNS carriers)) (PP (IN of) (NP (NP (DT the) (NN G) (NN allele)) (PP (IN in) (NP (NP (NP (JJ single) (NN nucleotide) (NN polymorphism)) (NN A118G)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-)))))))))))) (, ,) (CC and) (S (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ homozygous) (PP (IN for) (NP (DT the) (NN A) (NN allele)))))))) (VP (VBD were) (ADJP (RBR more) (JJ likely)) (S (VP (TO to) (VP (VB affiliate) (PP (IN with) (NP (NN alcohol) (NN use))) (S (VP (VBG promoting) (NP (NP (NNS peers)) (SBAR (WHNP (WP who)) (S (VP (VBD increased) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (NN drug2) (NNS symptoms)))) (PP (IN at) (NP (DT all) (NNS ages)))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN COMT) (NN drug1) (NN gene) (NN polymorphism)) (VP (VBZ has) (VP (VBN been) (VP (VBN investigated) (PP (IN as) (NP (NP (DT a) (NN susceptibility) (NN factor)) (PP (IN for) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (S (NP (DT No) (ADJP (RB statistically) (JJ significant)) (NNS results)) (VP (VBD were) (VP (VBN found) (PP (IN in) (NP (NN meta-analysis)))))) (CC but) (S (NP (CD one) (NN study)) (VP (VBD reported) (SBAR (IN that) (S (NP (DT the) (NN drug1) (NN allele)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NN drug2)))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN COMT) (NN drug1) (NN polymorphism)) (VP (VBD was) (ADVP (RB also)) (VP (VBN found) (S (VP (TO to) (VP (VB modulate) (NP (NN drug2)) (PP (IN in) (NP (NP (JJ normal) (NN people)) (CC and) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Whites)) (PP (IN with) (NP (NP (NN allele) (NN G)) (PP (IN of) (NP (NP (DT the) (JJ functional) (NN polymorphism) (NN 118A) (NN >) (NN G)) (PRN (-LRB- -LRB-) (NP (NN reference) (NN sequence) (NN drug1)) (-RRB- -RRB-))))))) (VP (VBD showed) (NP (NP (DT a) (JJR smaller) (NN decrease)) (PP (IN in) (NP (NN drug2)))))) (: ;) (S (NP (NP (DT those)) (VP (VBG bearing) (NP (NP (NP (JJ minor) (NNS alleles)) (NP (NP (NN IVS1)) (CC +) (NP (NN 1050A)))) (, ,) (NP (NP (NN IVS1)) (CC +) (NP (NN 14123A))) (, ,) (CC and) (NP (NP (NN IVS2)) (CC +) (NP (NN 31A)))))) (VP (VBD showed) (NP (NP (DT a) (JJR larger) (NN decrease)) (PP (IN in) (NP (NN drug3)))) (PP (IN over) (NP (NP (NN interval) (NN X)) (PRN (-LRB- -LRB-) (NP (CD 0.01) (NN <) (NN P) (NN <) (CD .05)) (-RRB- -RRB-))))))))
(S1 (S (S (NP (VBG Conflicting) (NNS results)) (VP (VBD were) (VP (VBN reported) (PP (IN on) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (DT the) (NP (NP (JJ mu-opioid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN OPRM1)) (-RRB- -RRB-))) (NN polymorphism) (NN A118G)) (PRN (-LRB- -LRB-) (NP (NP (NN Asn40Asp)) (, ,) (NP (NN drug1))) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN drug2)))))))))) (. .)))
(S1 (S (NP (NN drug3)) (VP (VBD were) (ADJP (ADJP (RBR more) (JJ sensitive) (PP (TO to) (NP (JJ experimental) (NN pain)))) (PP (PP (IN than) (NP (JJ healthy) (NNS volunteers))) (CC and) (, ,) (PP (IN in) (NP (JJ particular))) (, ,) (NP (NP (NP (NP (NN drug4) (NNS individuals)) (PP (IN with) (NP (NP (DT the) (NN met/met) (NN genotype)) (PRN (-LRB- -LRB-) (NP (NN drug1) (NN SNP)) (-RRB- -RRB-))))) (CC or) (NP (DT the) (JJ HPS-APS) (NNS haplotypes))) (VP (VBG showing) (NP (JJR higher) (NN drug5) (NNS stimuli))))) (PP (IN than) (NP (NP (NNS patients)) (VP (VBG carrying) (NP (NP (DT the) (NN LPS) (NN haplotype)) (CC or) (NP (NP (NN val) (NNS alleles)) (PRN (-LRB- -LRB-) (NP (CD drug2) (NN NP)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (PP (VBG According) (PP (IN with) (NP (JJ previous) (NN research)))) (, ,) (NP (PRP$ our) (NNS findings)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (NNS haplotypes)) (PP (IN of) (NP (NP (DT the) (NN COMT) (NN geneand) (NNS genotypes)) (PP (IN of) (NP (DT the) (NN drug1) (NN polymorphism)))))) (VP (VBP play) (NP (DT a) (JJ key) (NN role)) (PP (IN on) (NP (NN pain) (NN sensitivity))) (PP (IN in) (NP (NN drug2)))))))) (. .)))
(S1 (S (NP (PRP we)) (VP (VBD assessed) (NP (CD 10) (JJ case-control) (NNS studies)) (VP (VBD included) (NP (NP (NP (CD 7,067) (NNS cases)) (CC and) (NP (CD 9,374) (NNS controls))) (PP (IN of) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NN CYP1B1) (NNS SNPs)) (PP (IN of) (NP (NP (NN Leu432Val) (NN drug1) (NNP Asn453Ser) (NNP drug2) (, ,) (NNP Ala119Ser) (NNP drug3) (, ,) (NP (NN drug4))) (ADJP (JJ nd) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug5)))))))))))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (EX there)) (VP (VBZ is) (NP (NP (DT no) (JJ direct) (NN effect)) (PP (IN of) (NP (NN drug1) (NN genotype))) (PP (IN on) (NP (NP (DT the) (NN risk)) (PP (IN for) (NP (NN drug2))) (PP (IN among) (NP (JJ active) (NN heroin) (NNS users))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBD aimed) (S (VP (TO to) (VP (VB investigate) (NP (NP (NP (NNS associations)) (PP (IN between) (NP (NP (JJ subjective) (NN response)) (PP (TO to) (NP (NN drug2)))))) (CC and) (NP (NP (NP (JJ genetic) (NNS polymorphisms)) (CC and) (NP (NNS haplotypes))) (PP (IN in) (NP (NP (DT the) (JJ u-opioid) (NN receptor)) (PP (VBG including) (NP (NP (DT the) (JJ exonic) (NN variant) (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN Asp40Asn)) (-RRB- -RRB-))))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN study)) (VP (VBD was) (VP (VBN focused) (PP (IN on) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NP (NP (DT the) (JJ functional) (NN A118G) (NN polymorphism)) (PP (IN of) (NP (DT the) (NN OPRM1) (NN gene)))) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2)) (PP (IN in) (NP (NP (NNS groups)) (PP (IN of) (NP (NP (CD 130) (JJ male) (NNS patients)) (CC and) (NP (CD 452) (JJ male) (NNS controls)))))))))))))) (. .)))
(S1 (S (S (S (NP (NP (DT The) (NNS results)) (PP (IN of) (NP (DT the) (JJ present) (NN study)))) (VP (VBP reveal) (SBAR (IN that) (S (NP (DT the) (NN drug1) (NN gene) (NN polymorphism)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NP (DT a) (JJR better) (NN glucose) (NN tolerance)) (CC and) (NP (JJ improved) (VBZ IS))) (, ,) (SBAR (WHNP (NP (DT both)) (WHPP (IN of) (WHNP (WDT which)))) (VP (VBP suggest) (NP (NP (DT a) (JJ potential) (JJ protective) (NN effect)) (PP (IN of) (NP (DT this) (NN variant))) (PP (IN on) (NP (NN drug2) (NN risk)))))))))))))) (. .)) (. .)))
(S1 (S (ADVP (RB Moreover)) (, ,) (NP (PRP we)) (VP (VBD found) (SBAR (IN that) (S (S (NP (DT the) (NN drug1) (NN allele)) (VP (VBD was) (NP (NP (DT a) (JJ dose-response) (JJ protective) (NN factor)) (PP (IN for) (NP (NN drug2)))))) (CC and) (S (NP (DT the) (NN epsilon3) (NN allele)) (VP (VBD exerted) (NP (NP (DT a) (JJR weaker) (JJ dose-response) (JJ protective) (NN effect)) (PP (IN for) (NP (NP (NN risk)) (PP (IN of) (NP (NN AD)))))) (PP (VBN compared) (PP (IN with) (NP (NN epsilon2))))))))) (. .)))
(S1 (S (S (NP (NN drug1)) (VP (VBD was) (RB not) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (PRP$ our) (NN sample)))))))) (. .)))
(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (S (NP (JJ Previous) (NNS studies)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NN CTLA-4)) (-RRB- -RRB-))) (CC and) (NP (NP (NN drug2) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-a)) (-RRB- -RRB-))))) (PP (IN in) (NP (NP (NN carcinogenesis)) (PP (IN of) (NP (NN osteosarcoma))))))))) (, ,) (CC but) (S (NP (PRP$ their) (NNS results)) (VP (VBD were) (ADJP (JJ inconsistent))))) (. .))))
(S1 (S (NP (NP (JJ Pooled) (NNS results)) (VP (VP (VBD showed) (SBAR (IN that) (S (NP (NP (NN drug1) (NN polymorphism)) (PP (IN of) (NP (NN CTLA-4)))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NN drug2)))))))) (-LRB- -LRB-)))))
(S1 (S (S (NP (DT No) (JJ significant) (NNS associations)) (VP (VBD were) (VP (VBN found) (PP (IN between) (NP (NP (NP (NN drug1) (NN polymorphism)) (PP (IN of) (NP (NN CTLA-4)))) (CC or) (NP (NP (NN drug2) (NN polymorphism)) (PP (IN of) (NP (NP (NN TNF-a)) (CC and) (NP (NN drug3) (NN risk)))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN COMT) (NN drug1) (NN genotype)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (JJR higher) (NNS drug2)) (PP (IN on) (NP (DT the) (NN BIS-11) (NN second-order) (NN factor) (NN Non-planning)))))))) (. .)))
(S1 (S (PP (IN In) (NP (DT the) (JJ total) (NN population))) (, ,) (NP (NP (NN inheritance)) (PP (IN of) (NP (NP (DT the) (NN IL1R2) (NN drug1) (NNS AA)) (, ,) (NP (NP (NN drug2) (NN AA)) (, ,) (NP (NN TNF) (NN drug3) (NP (NN GA)) (CC +) (NP (NN AA))) (, ,) (CC and) (NP (NN TNF) (NN rs673) (NN GA)))))) (ADVP (RB genotypesmodestly)) (VP (VBD increased) (NP (NN drug4) (NN risk)) (PP (IN by) (NP (NN 1.45))) (PP (TO to) (NP (NP (NN 11.7-fold)) (ADJP (JJ relative) (PP (TO to) (NP (DT the) (NN referent) (NN genotype))))))) (. .)))
(S1 (S (S (PP (IN Among) (NP (NN U.S.) (NNS men))) (, ,) (NP (NP (JJ age-adjusted) (ADJP (ADJP (JJ dominant)) (, ,) (ADJP (JJ recessive)) (CC and) (ADJP (JJ additive))) (JJ genetic) (NNS models)) (PP (IN for) (NP (DT the) (NN IL1R2) (NN drug1) (NN locus)))) (VP (VBD were) (VP (VBN linked) (PP (TO to) (NP (NP (DT an) (NN increase)) (PP (IN in) (NP (NN drug2) (NN susceptibility)))))))) (. .)))
(S1 (S (PP (IN As) (PP (IN for) (NP (NN drug1) (NN polymorphism)))) (, ,) (NP (DT the) (JJ heterogeneous) (NN genotype)) (VP (VBD showed) (NP (NP (DT a) (VBN decreased) (NN risk)) (PP (IN for) (NP (NN drug2)))) (PP (VBN compared) (PP (IN with) (NP (NP (DT the) (JJ common) (NN homogenous) (NN genotype)) (PP (IN in) (NP (DT a) (JJ fixed-effect) (NN model))) (PP (IN in) (NP (NP (JJ Asian) (NN population)) (PRN (-LRB- -LRB-) (NP (NNP Met/Val)) (CC vs)))))))) (. .)))
(S1 (S (SBAR (IN In) (NN order) (S (VP (TO to) (VP (VB study) (NP (NP (JJ specific) (NNS features)) (PP (IN of) (NP (NP (NP (JJ remitting) (JJ multiple) (NN sclerosis)) (NNS patients)) (PP (IN with) (NP (NP (JJ different) (NNS genotypes)) (PP (IN of) (NP (NP (JJ polymorphic) (NNS loci)) (NP (NP (NN rs1800629) (NN gene) (NN TNFa)) (, ,) (NP (NN drug1) (NN gene) (NN CD40)) (, ,) (NP (NN drug2) (NN gene) (NN KIF1B)) (, ,) (NP (NN drug3) (NN IL-18) (NN gene)) (, ,) (VP (VBN conducted) (NP (NP (ADJP (ADJP (JJ clinical)) (CC and) (ADJP (JJ electrophysiological))) (NN examination)) (PP (IN of) (NP (NP (CD 149) (NNS patients)) (PP (IN with) (NP (NN drug4))))))))))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (VP (VBN determined) (NP (NP (NP (CD 4) (JJ frequent) (JJ nonsynonymous) (NN gene) (NNS polymorphisms)) (PP (IN of) (NP (NP (NN CYP1B1)) (PP (IN in) (NP (DT the) (JJ human) (NN drug5) (NN cell) (NNS lines)))))) (NP (NP (NNS panels)) (PP (IN of) (NP (NP (NP (DT the) (JJ National) (NN Cancer) (NN Institut) (NN e)) (PRN (-LRB- -LRB-) (NP (NN NCI)) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (JJ Japanese) (NN Foundation)) (PP (IN for) (NP (NP (NN Cancer) (NN Research)) (PRN (-LRB- -LRB-) (NP (NN JFCR)) (-RRB- -RRB-)))))))) (: :) (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NNP R48G)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NNP A119S)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NNP L432V)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN drug4))) (PRN (-LRB- -LRB-) (NP (NN N453S)) (-RRB- -RRB-))))))) (. .)))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (NN Evidence)) (VP (VBZ has) (VP (VBN suggested) (SBAR (IN that) (S (S (NP (NP (NP (NN tumour) (NN necrosis) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TNF)) (-RRB- -RRB-))) (NN -a)) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN aetiology)) (PP (IN of) (NP (NN drug3))))))))) (, ,) (CC but) (S (NP (NP (DT the) (JJ underlying) (NN association)) (PP (IN of) (NP (DT the) (NN TNF-a) (NNS polymorphisms) (NP (NP (NP (NN -238G/A)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (CC and) (NP (NP (NN -308G/A)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))))) (PP (IN with) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug4)))))) (VP (VBZ is) (ADVP (RB still)) (VP (VBN unconfirmed))))))))) (. .))))
(S1 (S (NP (NN Evidence)) (VP (VBZ has) (VP (VBN suggested) (SBAR (IN that) (S (S (NP (NP (NP (NN tumour) (NN necrosis) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN TNF)) (-RRB- -RRB-))) (NN -a)) (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN aetiology)) (PP (IN of) (NP (NN psoriasis))))))))) (, ,) (CC but) (S (NP (NP (DT the) (JJ underlying) (NN association)) (PP (IN of) (NP (DT the) (NN TNF-a) (NNS polymorphisms) (NP (NP (NN -238G/A) (NN drug1)) (CC and) (NP (NN -308G/A) (NN drug2))))) (PP (IN with) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug3)))))) (VP (VBZ is) (ADVP (RB still)) (NP (NN <ModMar>unconfirmed<ModMar>))))))))))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (PRP We)) (VP (VBP have) (VP (VBN confirmed) (NP (NP (NNS associations)) (PP (IN between) (NP (NP (NN drug3)) (CC and) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))))))) (. .))))
(S1 (S (NP (NP (NN Objective)) (: :) (S (NP (PRP We)) (VP (VBP have) (VP (VBN conducted) (NP (NP (DT the) (JJ first) (NN study)) (PP (IN of) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NP (NN interleukin) (-LRB- -LRB-) (NN IL) (-RRB- -RRB-) (CD -10)) (, ,) (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-a)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ drug1) (NN region) (JJ single) (NN nucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NNS SNPs)) (-RRB- -RRB-))))) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (NN Western) (NN Algeria))))))))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP show) (NP (NP (DT a) (JJ potential) (NN influence)) (PP (IN of) (NP (DT the) (NN drug1) (NN deletion))) (PP (IN on) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (NN drug2) (NN disease))) (PP (IN among) (NP (NP (NNS patients)) (PP (IN with) (NP (NN drug3)))))))))) (. .)))
(S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT no) (NN association)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NN drug2)))) (PP (IN in) (NP (NP (DT the) (JJ combined) (NN sample)) (PRN (-LRB- -LRB-) (NP (NN n=4071)) (, ,) (NP (NN p=0.110)) (, ,) (NP (NNS odds) (NP (CD ratio=1.08))) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP do) (RB not) (VP (VB support) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (DT the) (JJ Han) (JJ Chinese) (NN population))))))))) (. .)))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (S (NP (NP (NNS Genotypes)) (PP (IN of) (NP (NP (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN TNF-a)) (-RRB- -RRB-))) (CC and) (NP (NP (PRP$ its) (NN surface) (NNS receptors)) (, ,) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (, ,))))) (VP (VBP have) (VP (VBN been) (VP (VBN examined) (PP (IN in) (NP (NP (NNS terms)) (PP (IN of) (NP (NP (NP (DT the) (NN progression)) (, ,) (NP (NN metastasis)) (, ,) (NP (JJ clinical) (NN efficacy)) (, ,) (CC and) (NP (NN prognosis))) (PP (IN of) (NP (JJ various) (NNS cancers))))))))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (JJ little)) (VP (VBZ is) (VP (VBN known) (PP (IN about) (NP (NP (PRP$ their) (NNS effects)) (PP (IN on) (NP (NP (JJ clinical) (NN outcome)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN ESCC)) (-RRB- -RRB-)))))))))))))) (. .))))
(S1 (S (S (NP (NN drug1) (NN genotype)) (VP (VBZ is) (ADJP (JJ predictive) (PP (IN of) (NP (NP (JJ clinical) (NN response)) (PP (IN after) (NP (NP (NN treatment)) (PP (IN with) (NP (NP (JJ definitive) (JJ 5-fluorouracil/cisplatin-based) (NN chemoradiotherapy)) (PP (IN in) (NP (NP (JJ Japanese) (NNS patients)) (PP (IN with) (NP (JJ esophageal) (JJ squamous) (NN cell) (NN drug2)))))))))))))) (. .)))
(S1 (S (ADVP (RB Overall)) (, ,) (NP (NN TNF-a) (NN drug1) (NN polymorphism)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug2))))) (PP (IN under) (NP (CD four) (JJ genetic) (NN comparison) (NNS models)))))))
(S1 (S (S (ADVP (RB Remarkably)) (, ,) (NP (NN drug1)) (VP (VBD was) (NP (NP (DT a) (JJ protective) (NN factor)) (PP (TO to) (NP (NN drug2)))) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (IN with) (NP (NN BPH)))))) (PRN (-LRB- -LRB-) (NP (NP (NN OR=0.550)) (: ;) (NP (CD 95) (NN %) (CD CI=0.311-0.975))) (-RRB- -RRB-)) (, ,) (SBAR (IN although) (S (NP (DT the) (ADJP (RB statistically) (JJ significant)) (NN difference)) (VP (VBD was) (VP (VBN lost) (PP (IN after) (NP (NP (NN correction)) (PP (IN for) (NP (JJ multiple) (NNS comparisons))))))))))) (. .)))
(S1 (S (S (NP (NP (DT No) (JJ significant) (NNS associations)) (PP (IN of) (NP (NN drug1) (NN variant)))) (VP (VBD were) (VP (VBN observed) (PP (IN with) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC or) (NP (NN drug4) (NN clinicopathologic) (NN status))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBP have) (VP (VBN determined) (NP (NP (NP (CD 4) (JJ frequent) (JJ nonsynonymous) (NN gene) (NNS polymorphisms)) (PP (IN of) (NP (NP (NN CYP1B1)) (PP (IN in) (NP (DT the) (JJ human) (NN tumor) (NN cell) (NNS lines)))))) (NP (NP (NNS panels)) (PP (IN of) (NP (NP (NP (DT the) (JJ National) (NN CancerInstitute)) (PRN (-LRB- -LRB-) (NP (NN NCI)) (-RRB- -RRB-))) (CC and) (NP (NP (NP (DT the) (JJ Japanese) (NN Foundation)) (PP (IN for) (NP (NN drug5) (NN Research)))) (PRN (-LRB- -LRB-) (NP (NN JFCR)) (-RRB- -RRB-)))))) (: :) (NP (NP (NP (NP (NN drug1)) (PRN (-LRB- -LRB-) (NP (NNP R48G)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NNP A119S)) (-RRB- -RRB-))) (, ,) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NNP L432V)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN drug4))) (PRN (-LRB- -LRB-) (NP (NN N453S)) (-RRB- -RRB-))))))))
(S1 (S (S (NP (NP (CD Seven) (JJ polymorphic) (NNS variants)) (PP (IN in) (NP (NNS genes) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (NP (NN drug5)) (, ,) (NP (NN drug6)) (CC and) (NP (NN drug7)))))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NN drug8)))))) (. .)))
(S1 (S (ADVP (RB Noteworthy)) (, ,) (NP (NP (DT the) (JJ considerable) (NN number)) (PP (IN of) (NP (NP (NNS patients)) (VP (VBG carrying) (NP (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (NNS alleles)))))) (VP (VBZ underlies) (NP (NP (DT the) (NN importance)) (PP (IN of) (S (VP (VBG considering) (NP (NP (JJ pharmacogenetic) (NN testing)) (PP (IN before) (S (VP (VBG starting) (NP (NN drug) (NN therapy)) (S (NP (NNS protocols)) (VP (TO to) (VP (VB prevent) (NP (NP (NN toxicity)) (CC and/or) (NP (NP (NN lack)) (PP (IN of) (NP (NN effectiveness))) (PP (IN in) (NP (NP (NN drug3)) (CC or) (NP (NN drug4) (NN virus) (NNS infections)))))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Logistic) (NN regression) (NN analysis)) (VP (VBD identified) (NP (NP (NP (CD two) (NNS variants)) (VP (VBN associated) (PP (IN with) (NP (NN drug3))))) (, ,) (NP (NP (DT the) (JJ 32-bp) (NN deletion)) (PP (IN within) (NP (NN drug1)))) (CC and) (NP (NP (DT the) (NN drug2)) (PP (IN within) (NP (DT the) (NN MTHFR) (NN gene))))))) (. .)))
(S1 (S (S (NP (JJ Univariate) (NN analysis)) (VP (VBD detected) (NP (NP (NP (NP (CD one) (JJ significant) (NN single-nucleotide) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.03)) (-RRB- -RRB-))) (, ,) (NP (NN drug1)) (, ,)) (PP (IN within) (NP (NP (DT the) (NP (NP (NN methylenetetrahydrofolate) (NN reductase)) (PRN (-LRB- -LRB-) (NP (NN MTHFR)) (-RRB- -RRB-))) (NN gene)) (VP (VBN associated) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (JJ Logistic) (NN regression) (NN analysis)) (VP (VBD identified) (NP (NP (NP (CD two) (NNS variants)) (VP (VBN associated) (PP (IN with) (NP (NN drug3))))) (, ,) (NP (NP (DT the) (JJ 32-bp) (NN deletion)) (PP (IN within) (NP (NN drug1)))) (CC and) (NP (NP (NP (DT the) (NN p.222A/V) (NN variant)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-))) (PP (IN within) (NP (DT the) (NN MTHFR) (NN gene))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD explored) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP (NNS interactions)) (PP (IN between) (NP (NP (NNS polymorphisms)) (VP (VBG acting) (PP (IN upon) (NP (NP (NP (JJ postsynaptic) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NP (NN DRD2) (NN TaqA1) (NN drug1)) (CC and) (NP (JJ DRD4) (NN 7R))) (-RRB- -RRB-))) (CC and) (NP (NP (NN dopamine) (NNS regulators)) (PRN (-LRB- -LRB-) (NP (NP (NN COMT) (NN drug2)) (CC and) (NP (NN DAT1))) (-RRB- -RRB-)))))))))) (PP (IN on) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NN drug3)) (CC and) (NP (NN personality) (NNS traits)))) (PP (IN in) (NP (NP (NNS women)) (PP (IN with) (NP (NN drug4))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD observed) (NP (NP (CD two) (JJ epistatic) (NNS interactions)) (PP (IN on) (NP (NN symptom) (NNS indices)))))) (: :) (S (NP (NP (NP (NNS interactions)) (PRN (-LRB- -LRB-) (PP (IN in) (NP (VBN predicted) (NNS directions))) (-RRB- -RRB-))) (PP (IN of) (NP (NN drug1)))) (VP (VBD were) (VP (VBN seen) (PP (PP (IN on) (NP (NP (NN drug3)) (PRN (-LRB- -LRB-) (NP (NN p=.023)) (-RRB- -RRB-)))) (, ,) (CC and) (PP (IN of) (NP (NN drug2))) (PP (IN on) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN p=.014)) (-RRB- -RRB-)))))))) (, ,)))
(S1 (S (NP (NP (NP (NN STUDY) (NNS PURPOSES)) (: :)) (, ,) (NP (NP (NN Analysis)) (PP (IN of) (NP (NP (NN influence)) (PP (IN of) (NP (NP (JJ allelic) (NNS polymorphisms)) (NP (NP (NNP C1444T)) (PP (IN of) (NP (NP (NN CRP) (NN gene) (NN drug1)) (, ,) (NP (NP (NN G) (-LRB- -LRB-) (CD -174) (-RRB- -RRB-) (NN A)) (PP (IN of) (NP (NN IL6) (NN gene) (NN drug2)))) (, ,) (NP (NP (DT A) (-LRB- -LRB-) (CD -308) (-RRB- -RRB-) (NN G)) (PP (IN of) (NP (NN TNF) (NN gene) (NN drug3)))) (, ,) (NP (NP (NNP G252A)) (PP (IN of) (NP (NN LTA) (NN gene) (NN drug4)))) (, ,))) (-LRB- -LRB-) (CD -509) (-RRB- -RRB-)))) (PP (IN of) (NP (NN TGFB1) (NN gene) (NN drug5)))))) (CC and) (NP (NP (NP (NN delta32)) (PRN (-LRB- -LRB-) (NP (NN w/d)) (-RRB- -RRB-))) (PP (IN of) (NP (NN CCR5) (NN gene) (NN drug6))) (PP (IN on) (NP (NP (NN development)) (PP (IN of) (NP (NP (NN drug7)) (PP (IN in) (NP (NP (JJ Russian) (NNS patients)) (PP (IN with) (NP (NN MI))))) (PP (IN during) (NP (NP (CD two) (NNS years)) (NN follow-up)))))))))))
(S1 (S (NP (NP (NNS Methods)) (: :) (S (NP (NP (DT A) (NN total)) (PP (IN of) (NP (NP (NP (CD 51) (NN drug12) (NNS patients)) (CC and) (NP (CD 96) (JJ unrelated) (NNS controls))) (PP (IN from) (NP (NP (NNP West) (NN region)) (PP (IN of) (NP (NNP Algeria)))))))) (VP (VBD were) (VP (VBN genotyped) (PP (IN by) (NP (NP (JJ direct) (NN sequencing)) (PP (IN for) (NP (NP (CD 11) (NNS SNPs)) (PP (VBG including) (NP (NP (NP (NP (CD 2) (NNS SNPs)) (PP (IN from) (NP (DT the) (NN IL10) (NN promoter) (NN -LSB-c.-819T) (NN >) (NN C) (NN drug1)))) (, ,) (NP (NP (NN c.-592A) (NN >) (NN C) (NN drug2)) (, ,) (NP (NP (CD 6) (NNS SNPs)) (PP (IN from) (NP (DT the) (NN TNF-a) (NN promoter) (NN -LSB-c.-1211T) (NN >) (NN C) (NN drug3)))) (, ,) (NP (NN c.-1043C) (NN drug4)) (, ,) (NP (NN c.-1037C) (NN >) (NN T) (NN drug5)) (, ,) (NP (NN c.-556G) (NN >) (NN A) (NN drug6)) (, ,) (NP (NN c.-488G) (NN >) (NN A) (NN drug7)) (, ,) (CC and) (NP (NN c.-418G) (NN >) (NN A) (NN drug8)) (-RRB- -RSB-)) (, ,)) (CC and) (NP (NP (CD 3) (NNS SNPs)) (PP (IN from) (NP (NP (DT the) (NN IL23R-IL12RB2) (NN region) (NN -LSB-g.67747415A) (NN >) (NN C) (CD drug9)) (, ,) (NP (NN g.67740092G) (NN >) (NN A) (CD drug10)) (, ,) (CC and) (NP (NN g.67760140T) (NN >) (NN C) (CD drug11) (-RRB- -RSB-)))))))))))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (JJ VARIOUS) (NNS SNPS)) (VP (VBD REACHED) (NP (JJ NOMINAL) (NN SIGNIFICANCE)) (: :) (NP (NP (NP (NP (CD drug12)) (CC and) (NP (CD drug13))) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))))) (, ,) (NP (NP (CD drug14)) (PP (IN with) (NP (NN drug3)))) (, ,) (NP (NP (CD drug15)) (PP (IN with) (NP (NN drug4)))) (, ,) (NP (NP (CD drug16)) (PP (IN with) (NP (NP (NN drug5)) (CC and) (NP (NN drug6))))) (, ,) (NP (NP (CD drug17)) (PP (IN with) (NP (NN drug7)))) (, ,) (NP (NP (CD drug18)) (PP (IN with) (NP (NN drug8)))) (, ,) (NP (NP (CD drug19)) (PP (IN with) (NP (NN drug9)))) (, ,) (NP (CD drug10)) (CC and) (NP (CD drug11))))) (. .))))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (NP (NP (NP (DT a) (JJ significant) (NN genotype) (NN effect)) (PRN (-LRB- -LRB-) (NP (NN all) (CD P<0.017)) (-RRB- -RRB-))) (PP (IN for) (NP (DT the) (JJ following) (JJ smoking-related) (NNS phenotypes)))))) (: :) (S (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (NP (NNS cigarettes)) (VP (VBN smoked) (PP (IN per) (NP (NP (NN day)) (CC and) (NP (NN CYP2A13) (NN *) (CD 3)))))) (: ;) (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (S (NP (NN pack) (NNS years)) (VP (VBD smoked) (NP (CC and) (NP (NN CYP2A6) (NN *) (CD 2)) (, ,) (NP (NN CYP2A6) (NN *) (CD 1) (NN *) (CD 2)) (, ,) (NP (NN drug1)) (, ,) (NP (NN CYP2B6) (NN *) (CD 4)) (CC and) (NP (NP (NN DRD2-ANKK1) (NN 2137G>A)) (PRN (-LRB- -LRB-) (NP (NN Taq1A)) (-RRB- -RRB-)))))) (: ;) (NP (NP (NP (LST (-LRB- -LRB-) (LS iii) (-RRB- -RRB-)) (NN drug3)) (PRN (-LRB- -LRB-) (VP (VBN assessed) (PP (IN with) (NP (DT the) (NN Fagestrom) (NN test)))) (-RRB- -RRB-))) (CC and) (NP (NN drug2))) (. .)))
(S1 (S (S (NP (NP (DT The) (JJ best-studied) (JJ functional) (JJ genetic) (NN variant)) (ADJP (JJ relevant) (PP (TO to) (NP (NN drug2) (NN treatment))))) (VP (VBZ is) (NP (NP (NN drug1)) (, ,) (NP (NP (DT a) (JJ single-nucleotide) (NN polymorphism)) (PP (IN in) (NP (NP (NN exon) (CD 1)) (PP (IN of) (NP (DT the) (NN OPRM1) (NN gene))))) (SBAR (WHNP (WDT that)) (S (VP (VBZ encodes) (NP (DT the) (JJ u-opioid) (NN receptor))))))))) (. .)))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (NP (DT The) (NN association)) (PP (IN between) (NP (NP (DT the) (NN OPRM1) (NN A118G) (-LRB- -LRB-) (NN Asn40Asp) (, ,) (NN drug1) (-RRB- -RRB-) (NN polymorphism)) (CC and) (NP (NP (NN drug2)) (CC and) (NP (NN alcohol) (NN consumption)))))) (VP (VBD was) (VP (VBN analyzed) (S (VP (VBG using) (NP (CD three) (JJ different) (JJ population-based) (NNS samples))))))) (: :) (NP (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-)) (NP (NP (NP (DT a) (NN Finnish) (NN cohort) (NN study)) (, ,) (NP (NN Health) (CD 2000)) (, ,)) (PP (IN with) (NP (NP (CD 503) (NNS participants)) (VP (VBG having) (NP (NP (DT a) (JJ DSM-IV) (NN diagnosis)) (PP (IN for) (NP (NP (NP (NN drug3)) (CC and/or) (NP (NN drug4))) (CC and) (NP (NP (CD 506) (NN age-)) (CC and) (NP (JJ sex-matched) (NNS controls)))))))))) (: ;) (NP (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-)) (NP (DT a) (NN Finnish) (NN cohort) (NN study))) (, ,) (NP (NP (NN FINRISK)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 2360)) (-RRB- -RRB-))) (CC and) (NP (LST (-LRB- -LRB-) (LS c) (-RRB- -RRB-)) (NP (DT the) (NN Helsinki) (NN Birth) (NN Cohort) (NN Study)) (PRN (-LRB- -LRB-) (NP (NN n) (JJ =) (CD 1384)) (-RRB- -RRB-)))) (. .))))
(S1 (S (PP (IN In) (NP (NP (DT the) (JJ case-control) (NN study)) (SBAR (WHNP (WDT that)) (S (VP (VBD included) (NP (NP (NP (NP (NNS 187patients)) (PP (IN with) (NP (NN drug2)))) (PRN (-LRB- -LRB-) (NP (NNS cases)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 189) (JJ normal) (NNS subjects)) (PRN (-LRB- -LRB-) (NP (NNS controls)) (-RRB- -RRB-))))))))) (, ,) (NP (NP (NP (DT the) (NN AA) (NN genotype)) (CC and) (NP (JJ variant) (NN Met) (NN allele) (NNS frequencies))) (PP (IN of) (NP (NN drug1))) (PP (IN in) (NP (DT the) (NN COMTgene)))) (VP (VBD were) (ADJP (ADJP (RB significantly) (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN drug3))))) (PP (IN than) (NP (NP (DT those)) (PP (IN in) (NP (NP (DT the) (NN control) (NN group)) (PRN (-LRB- -LRB-) (NP (DT both) (NN p) (NN <0.05)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (PP (VBN Compared) (PP (IN with) (NP (NNS nonsmokers)))) (, ,) (NP (NP (NN European-American) (NN COMT) (NN drug1) (JJ double-variant) (NNS carriers)) (SBAR (WHNP (WP who)) (S (VP (VBD smoked))))) (VP (VBD had) (NP (NP (NP (VBN increased) (NNS odds)) (PP (IN of) (NP (NN drug2)))) (NP (NP (JJ -LSB-adjusted) (NNS odds) (NN ratio)) (PRN (-LRB- -LRB-) (NP (NN AOR)) (-RRB- -RRB-) (NP (CD 6.15) (, ,) (CD 95) (NN %) (NN confidence) (NN interval) (-LRB- -LRB-) (NN CI) (-RRB- -RRB-) (CD 1.32-28.78)) (-RRB- -RRB-) (-RRB- -RSB-))))) (: ;)))
(S1 (S (NP (NP (NN European-American) (NN COMT) (NN drug1) (JJ double-variant) (NNS carriers)) (SBAR (WHNP (WP who)) (S (VP (VBD smoked) (ADVP (RB heavily)))))) (VP (VBD had) (NP (ADJP (ADJP (RBR more) (JJ frequent)) (ADJP (ADJP (JJ moderate)) (CC or) (ADJP (JJ severe)))) (NN drug2)) (PP (IN than) (NP (NP (NNS nonsmokers)) (PRN (-LRB- -LRB-) (NP (NN AOR) (CD 13.7)) (, ,) (S (NP (CD 95) (NN %)) (VP (JJ CI) (NP (CD 1.2-154.9)))) (-RRB- -RRB-))))) (. .)))
(S1 (S (S (NP (JJ European-American) (NN drug1)) (VP (JJ double-variant) (NP (NP (NNS carriers)) (SBAR (WHNP (WP who)) (S (VP (VBD smoked) (VP (VBD described) (NP (ADJP (RBR more) (JJ frequent)) (ADJP (ADJP (JJ moderate)) (CC or) (ADJP (JJ severe))) (NNS drug2)) (PP (IN than) (NP (ADJP (ADJP (JJ nonsmoking) (PRN (-LRB- -LRB-) (NP (NN AOR) (CD 20.6)) (, ,) (NP (NP (CD 95) (NN %)) (ADJP (JJR CI) (NP (CD 1.64-257.93)))) (-RRB- -RRB-))) (CC and) (ADJP (JJ never-smoking) (PRN (-LRB- -LRB-) (NP (NN AOR) (CD 20.59)) (, ,) (S (NP (CD 95) (NN %)) (VP (JJ CI) (NP (CD 1.39-304.68)))) (-RRB- -RRB-)))) (NNS carriers)))))))) (, ,) (ADVP (RB respectively)))) (. .)))
(S1 (S (S (NP (NP (JJ African-American) (JJ single-variant) (NN drug1) (NNS carriers)) (SBAR (WHNP (WP who)) (S (VP (VBD smoked))))) (VP (VBD were) (ADJP (RBR more) (JJ likely)) (S (VP (TO to) (VP (VBP report) (NP (NN drug2)) (PP (IN than) (NP (NP (DT the) (JJ nonsmoking) (NNS carriers)) (PRN (-LRB- -LRB-) (NP (NN AOR) (CD 6.16)) (, ,) (NP (NP (CD 95) (NN %)) (ADJP (JJR CI) (NP (CD 1.11-33.91)))) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN study)) (VP (VBD aimed) (S (VP (TO to) (VP (VB test) (NP (NP (DT the) (NN association)) (PP (IN between) (NP (NP (NP (DT the) (NN Val158Met) (NN polymorphism)) (NN drug1)) (PP (IN of) (NP (DT the) (JJ catechol-O-methyl) (NN transferase) (NN gene) (NN andanorexia) (NN nervosa) (NN drug2))))))))))) (. .)))
(S1 (S (NP (DT The) (JJ present) (NN association) (NNS studies)) (VP (VBD found) (NP (NP (DT no) (NN association)) (PP (IN between) (NP (NP (NN drug2)) (CC and) (NP (NN drug1))))) (SBAR (WHADVP (WRB when)) (S (VP (VBG testing) (NP (NP (DT the) (NP (JJ allelic) (NN contrast) (NN -LSB-Utrecht) (NNS odds)) (NN ratio)) (PRN (-LRB- -LRB-) (CC OR) (-RRB- -RRB-) (NP (NP (NN =1.14)) (, ,) (NP (NN P=0.14)) (: ;) (NP (NNP Leiden) (NNP OR=1.02) (, ,) (NNP P=0.85))) (-RRB- -RSB-))))))) (. .)))
(S1 (S (NP (NP (JJ Meta-analytically) (JJ combined) (NN evidence)) (PP (IN from) (NP (NP (DT the) (JJ present) (NNS genotypings)) (CC and) (NP (DT the) (NN literature) (NN search))))) (VP (VBZ shows) (SBAR (SBAR (IN that) (S (NP (DT the) (NN effect) (NNS sizes)) (VP (VBP are) (ADJP (JJ homogeneous) (PP (IN across) (NP (NNS studies))))))) (CC and) (SBAR (IN that) (S (NP (NN drug1)) (VP (VBZ is) (RB not) (VP (VBN associated) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (S (NP (NP (DT the) (NN COMT) (NN drug1) (NN SNP)) (SBAR (WHNP (WDT that)) (S (VP (VBZ reduces) (NP (NN enzyme) (NN activity))))) (, ,)) (VP (VBZ has) (ADVP (RB previously)) (VP (VBN been) (VP (VBN linked) (PP (TO to) (NP (NN drug2))))))) (. .)))
(S1 (S (S (NP (IN Although) (DT the) (NN drug1) (NN SNP)) (VP (VBD was) (RB not) (NP (NP (DT a) (NN risk) (NN factor)) (PP (IN for) (NP (NN drug2)))))) (. ,)))
(S1 (S (S (NP (PRP We)) (VP (VBP conclude) (SBAR (IN that) (S (NP (DT the) (JJ functional) (NN COMT) (NN drug1) (NN SNP)) (VP (VBZ contributes) (PP (TO to) (NP (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4))))))))) (. .)))
(S1 (S (NP (DT The) (NNS authors)) (VP (VBD examined) (NP (NP (NNS relations)) (PP (IN between) (NP (NP (JJ reproductive) (NNS factors)) (CC and) (NP (NP (CD 5) (NN estrogen) (NN pathway) (NN gene) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (NP (NN drug4)) (, ,) (CC and) (NP (NN COMT) (NN drug5))) (-RRB- -RRB-))))) (PP (IN among) (NP (NP (NP (CD 702) (NN Singapore) (JJ Chinese) (JJ female) (NN drug6) (NNS cases)) (CC and) (NP (NN 1,578) (NN hospital) (NNS controls))) (, ,) (SBAR (WHPP (IN of) (WHNP (WP whom))) (S (NP (NP (NP (CD 433) (NNS cases)) (PRN (-LRB- -LRB-) (NP (CD 61.7) (NN %)) (-RRB- -RRB-))) (CC and) (NP (NP (CD 1,375) (NNS controls)) (PRN (-LRB- -LRB-) (NP (CD 87.1) (NN %)) (-RRB- -RRB-)))) (VP (VBD were) (ADVP (RB never)) (NP (NNS smokers))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN COMT) (NN drug1) (NN A) (NN allele)) (VP (VBD was) (ADVP (RB positively)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (PP (IN in) (NP (NP (RB never) (NNS smokers)) (PRN (-LRB- -LRB-) (PP (IN for) (NP (NP (NN G/A)) (CC or) (NP (NP (NN A/A)) (CC vs.) (NP (NN G/G))))) (, ,) (NP (CC OR) (JJ =) (NP (NP (NP (QP (CD 1.46) (, ,) (CD 95)) (NN %)) (CD CI) (: :) (CD 1.12)) (, ,) (NP (CD 1.90)))) (-RRB- -RRB-)))) (CC but) (PP (RB not) (IN in) (NP (RB ever) (NNS smokers))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (PRP we)) (VP (VBD hypothesized) (SBAR (IN that) (S (S (LST (-LRB- -LRB-) (LS 1) (-RRB- -RRB-)) (NP (DT the) (NN COMT) (NN gene)) (VP (VBZ contributes) (PP (TO to) (NP (NN drug2))))) (CC and) (S (LST (-LRB- -LRB-) (LS 2) (-RRB- -RRB-)) (NP (NP (NP (DT a) (NN COMT) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (: :) (NP (NN Val158Met)) (-RRB- -RRB-))) (VP (VBG causing) (NP (NP (NN thermolability)) (PP (IN of) (NP (JJ enzymatic) (NN activity)))))) (VP (VBZ affects) (NP (NP (NN liver) (NNS enzymes)) (PRN (-LRB- -LRB-) (PP (FW e.g.) (, ,) (NP (NP (NP (NN aspartate) (NN aminotransferase)) (PRN (-LRB- -LRB-) (NP (NN AST)) (-RRB- -RRB-))) (, ,) (NP (NP (NN alanine) (NN aminotransferase)) (PRN (-LRB- -LRB-) (NP (NN ALT)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ gamma-glutamyl) (NN transpeptidase)) (PRN (-LRB- -LRB-) (NP (NN Î³-GT)) (-RRB- -RRB-))))) (-RRB- -RRB-))) (PP (IN in) (NP (NN serum))))))))) (. .)))
(S1 (S (ADVP (RB Recently)) (NP (PRP we)) (VP (VBD identified) (NP (NP (NP (NP (CD two) (NNS SNPs)) (PP (IN in) (NP (NN COMT)))) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (CC and) (NP (NN drug2))) (-RRB- -RRB-))) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug3)) (PP (IN in) (NP (DT an) (NN Australian) (NN cohort))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Individuals)) (PP (IN with) (NP (NN drug3)))) (VP (VBD were) (ADVP (RBR more) (IN than)) (ADJP (ADVP (RB twice) (RB as)) (JJ likely)) (S (VP (TO to) (VP (VBP carry) (NP (NP (DT the) (NN GG) (NN genotype)) (PP (VBN compared) (PP (TO to) (NP (DT the) (NN AA) (NN genotype)))) (PP (IN for) (NP (CC both) (DT the) (NP (NN drug1)) (CC and) (NP (NN drug2) (NNS SNPs)))))))))) (. .)))
(S1 (S (S (NP (NP (NN Association)) (PP (IN of) (NP (NP (CC both) (NP (NN drug1)) (CC and) (NP (NN drug2) (NN withsubstance) (NN dependence))) (, ,) (NP (NP (DT a) (JJ common) (NN comorbidity)) (PP (IN of) (NP (NN drug3))))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN investigated))))) (. .)))
(S1 (S (S (NP (DT The) (JJ drug1) (NN SNP)) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NN drug2)))))) (. .)))
(S1 (S (S (S (NP (DT The) (NN drug1) (NN SNP)) (VP (VBD showed) (NP (NP (DT a) (JJ weak) (NN association)) (PP (IN with) (NP (NN drug2)))) (PP (IN at) (NP (NP (DT the) (NN allele) (NN level)) (SBAR (WHNP (WDT that)) (S (VP (VBD did) (RB not) (VP (VB reach) (NP (NN significance)) (PP (IN at) (NP (DT the) (NN genotype) (NN level))))))))))) (CC but) (S (NP (PRP it)) (VP (VBD was) (RB not) (VP (VBN associated) (PP (IN with) (NP (NN drug3))))))) (. .)))
(S1 (S (S (NP (NP (NN Analysis)) (PP (IN of) (NP (NN drug1) (NNS haplotypes)))) (ADVP (RB also)) (VP (VBD revealed) (NP (NP (NN association)) (PP (IN with) (NP (NN drug2))) (PP (IN with) (S (NP (DT the) (NN G/Ghaplotype)) (VP (VBG being) (ADJP (QP (RB almost) (CD 1.5) (NNS times)) (RBR more) (JJ common) (PP (IN in) (NP (NN drug3) (NNS cases)))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (NP (DT the) (NN drug1) (NN SNP)) (, ,) (PP (IN in) (NP (NP (NN combination)) (PP (IN with) (NP (NN drug2))))) (, ,)) (VP (VBZ results) (PP (IN in) (NP (NP (NP (DT a) (JJ common) (JJ molecular) (NN variant)) (PP (IN of) (NP (NN COMT)))) (SBAR (WHNP (WDT that)) (S (VP (VBZ contributes) (PP (TO to) (NP (NP (NN drug3)) (CC and) (NP (NN drug4) (NN susceptibility)))))))))))))) (. .)))
(S1 (S (ADVP (RB However)) (, ,) (SBAR (WHADVP (WRB when)) (S (NP (DT this) (NN relation)) (VP (VBD was) (VP (VBN assessed) (PP (IN within) (NP (NP (NN strata)) (VP (VBN based) (PP (IN on) (NP (JJ estrogen-related) (NNS factors)))))))))) (, ,) (NP (NP (NP (DT a) (JJ few) (NN SNPs)) (PRN (-LRB- -LRB-) (NP (NN HSD17B1)) (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (CC and) (NP (NN drug3))) (-RRB- -RRB-))) (, ,) (NP (NP (NN COMT)) (PRN (-LRB- -LRB-) (NP (NN drug4)) (-RRB- -RRB-))) (, ,) (NP (NP (NN UGT1A1)) (PRN (-LRB- -LRB-) (NP (NN drug5)) (-RRB- -RRB-))) (CC and) (NP (NP (NN ESR1)) (PRN (-LRB- -LRB-) (NP (NN drug6)) (-RRB- -RRB-)))) (VP (VBD seemed) (S (VP (TO to) (VP (VB be) (ADJP (JJ related) (PP (TO to) (NP (NP (NN drug7)) (PP (IN in) (NP (NP (DT the) (JJ same) (NN direction)) (PP (IN of) (NP (NP (PRP$ their) (NNS associations)) (PP (IN with) (NP (NN drug8)))))))))))))) (. .)))
(S1 (S (NP (PRP we)) (VP (VBD examined) (NP (NP (NP (NNS variations)) (PP (IN in) (NP (ADJP (ADJP (JJ maternal)) (CC and) (ADJP (JJ fetal))) (NN COMT) (NNS genes)))) (CC and) (NP (NP (PRP$ their) (NN association)) (PP (IN with) (NP (NP (NN drug5)) (PRN (-LRB- -LRB-) (NP (NP (NN term)) (CC vs) (NP (JJ preterm) (NNS pregnancies))) (-RRB- -RRB-)))))) (S (VP (VBG using) (NP (NP (CD 4) (JJ functional) (NNS SNPs)) (: :) (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (, ,) (CC and) (NP (NN drug4))) (PP (IN in) (NP (CC both) (NP (NN AA)) (CC and) (NP (NN Cau))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (PRP$ our) (NN study)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT a) (JJ synonymous) (NN polymorphism)) (, ,) (NP (NP (NN drug1)) (PP (IN in) (NP (DT the) (JJ fetal) (NN COMT) (NN gene)))) (, ,)) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (NN AA))))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Variants)) (PP (IN of) (NP (NP (NN drug1) (NN drug2)) (CC and) (NP (NN drug3))))) (VP (VBD were) (RB not) (VP (VBN associated) (PP (IN with) (NP (NP (DT the) (NN risk)) (PP (IN of) (NP (VBG developing) (NNS drug4)))))))) (. .)))
(S1 (S (NP (NP (DT A) (JJ common) (NN C-G-C-C-G-A) (NN haplotype)) (PP (IN for) (NP (NP (NN drug1)) (: -) (NP (NN drug2)) (: -) (NP (NN drug3)) (: -) (NP (NN drug4)) (: -) (NP (NN drug5)) (: -) (NP (NN drug6))))) (VP (VBD showed) (NP (NP (DT an) (JJ inverse) (NN association)) (PP (IN with) (NP (NN drug7) (NN risk)))) (PP (PP (IN in) (NP (NP (NNP Hispanic) (NNP Caucasians)) (PRN (-LRB- -LRB-) (CC OR) (NP (NP (JJ =) (NN 0.19)) (, ,) (NP (NP (NN P)) (ADJP (JJ =) (NP (NP (ADJP (QP (CD 0.04) (, ,) (CD 95)) (NN %)) (NN CI)) (ADJP (JJ =) (NP (CD 0.04-0.95))))))) (-RRB- -RRB-)))) (CC and) (PP (IN with) (NP (NP (JJ aggressive) (NN disease) (NN status)) (PRN (-LRB- -LRB-) (PP (FW i.e.)) (NP (NN Gleason) (NN score) (JJ >or=7)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (JJ non-Hispanic) (NN Caucasian) (NNS cases)) (PRN (-LRB- -LRB-) (CC OR) (NP (JJ =) (ADJP (CD 0.64) (, ,) (NN P) (JJ =) (NP (QP (CD 0.008) (, ,) (CD 95)) (NN %))) (NN CI) (JJ =) (CD 0.47-0.89)) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NP (DT A) (NN subset)) (PP (IN of) (NP (CD 82) (NNS patients)))) (ADVP (RB also)) (VP (VBD underwent) (NP (NN drug8) (NN testing)))) (, ,) (S (NP (NNS Patients)) (VP (VBD were) (VP (VBN genotyped) (PP (IN for) (NP (NP (DT the) (NN MTHFR) (NN 677C>T) (NN drug1) (NN drug2)) (, ,) (NP (NN MTR) (NN 2756A>G) (NN drug3) (NN MTRR) (NN 203A>G) (NN drug4)) (, ,) (NP (NN FOLH1) (NN 484T>C) (NN drug5)) (, ,) (NP (NN RFC) (NN 80A>G) (NN drug6)) (CC and) (NP (NN COMT675G>A) (NN drug7) (NNS polymorphisms))))))) (. .)))
(S1 (S (S (NP (NP (NP (DT A) (JJ common) (NN Val->Met) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN COMT) (NN gene))) (, ,) (VP (VBN associated) (PP (IN with) (NP (VBN increased) (JJ prefrontal) (NN dopamine) (NN catabolism)))) (, ,)) (VP (VP (VBZ impairs) (NP (JJ prefrontal) (NN cognition))) (CC and) (VP (MD might) (VP (VB increase) (NP (NP (NN risk)) (PP (IN for) (NP (NN drug2)))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN found) (NP (NP (DT an) (NN association)) (PP (IN with) (NP (NP (NN drug1)) (CC and) (NP (NN drug2)) (NP (NN addiction)))))))) (. .)))
(S1 (S (S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ individual) (NN susceptibility)) (PP (TO to) (NP (NN drug4) (NN incidence)))) (VP (MD may) (VP (VB be) (VP (VBN increased) (PP (IN by) (NP (NP (JJ combined) (NNS effects)) (PP (IN of) (NP (DT the) (JJ high-risk) (NNS genotypes))) (PP (IN in) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3) (NN estrogen) (JJ metabolic) (NNS genes))))))))))))) (. .)))
(S1 (S (S (NP (NP (NP (DT The) (NN Val108/158Met) (NN drug1) (JJ single) (NN nucleotide) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN SNP)) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (NN catechol-O-methyltransferase) (-LRB- -LRB-) (NN COMT) (-RRB- -RRB-) (NN gene)))) (VP (VBZ contributes) (PP (TO to) (NP (NP (JJ genetic) (NN susceptibility)) (PP (TO to) (NP (NN drug2))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (ADVP (RB specifically)) (ADJP (JJ related) (PP (TO to) (NP (NP (NNS impairments)) (PP (IN in) (NP (NP (NN executive)) (VP (VBG functioning)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ different) (JJ genomic) (NN region)) (VP (VBN composed) (PP (IN of) (NP (NP (NP (CD three) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3))) (-RRB- -RRB-))) (PP (IN within) (NP (DT the) (NN COMT) (NN gene))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN reported) (S (VP (TO to) (VP (VB be) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug4)) (PP (IN in) (NP (JJ Ashkenazi) (NNS Jews))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN SNP) (NN drug1)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ has) (VP (VBN been) (VP (VBN mapped) (PP (TO to) (NP (NP (DT the) (NN 3'-UTR) (NN region)) (PP (IN of) (NP (DT the) (NN COMT) (NN gene)))))))))) (, ,)) (VP (VBD was) (VP (VP (ADVP (RB significantly)) (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PP (IN in) (NP (PRP$ our) (NN family) (NN study)))))) (, ,) (CC and) (VP (ADVP (RB possibly)) (VBN associated) (PP (IN with) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (NP (NN onset)) (, ,) (NP (NN delusion/hallucination) (NN symptom) (NN dimension)) (, ,) (CC and) (NP (NN CPT) (NN performance)))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN COMT)) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (DT the) (JJ genetic) (NN risk)) (PP (IN for) (NP (NN drug2))))) (PP (PP (RB not) (IN through) (NP (DT the) (NN drug1) (NN polymorphism))) (, ,) (CC but) (PP (IN through) (NP (NP (JJ other) (NNS variants)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (JJ situated) (NP (CD 3) ('' ')) (PP (TO to) (NP (DT this) (NN region))) (, ,) (PP (IN in) (NP (DT the) (NN Taiwanese) (NN population))))))))))))) (. .)))
(S1 (S (NP (NP (NN OBJECTIVE)) (: :) (S (NP (NP (DT The) (NN T) (NN allele)) (PP (IN of) (NP (NP (NP (DT a) (JJ functional) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (: :) (NP (CD LCT-13910) (NN C>T))) (-RRB- -RRB-))) (, ,) (ADJP (JJ close) (PP (TO to) (NP (DT the) (NN lactase) (NN gene)))) (, ,)))) (VP (VBZ correlates) (PP (IN with) (NP (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN LP)) (-RRB- -RRB-))) (PP (IN in) (NP (NNS adults))))))) (. .))))
(S1 (S (S (NP (PRP$ Our) (NN aim)) (VP (VBD was) (S (VP (TO to) (VP (VB test) (PP (IN in) (NP (DT this) (NN study))) (, ,) (NP (NP (DT the) (NN association)) (PP (IN of) (NP (NN drug1))) (PP (IN with) (NP (NP (NN BMI)) (CC and) (NP (JJ related) (NN drug2))))) (, ,) (PP (IN in) (NP (NP (NN interaction)) (PP (IN with) (NP (NN dairy) (NN product) (NN consumption)))))))))) (. .)))
(S1 (S (S (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN PLI)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN defined) (PP (IN as) (NP (NP (DT the) (NN C/C) (NN genotype)) (PP (IN of) (NP (DT the) (NN drug1) (NN polymorphism)))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD hypothesized) (SBAR (SBAR (IN that) (S (NP (NP (NNS individuals)) (PP (IN with) (NP (NP (DT the) (NN drug2) (NN allele)) (PP (IN of) (NP (NP (DT the) (JJ LCT) (NN SNP)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))))))) (VP (MD would) (VP (VB exhibit) (NP (NP (DT a) (JJR greater) (NN degree)) (PP (IN of) (NP (NN drug3)))))))) (CC and) (SBAR (IN that) (S (NP (DT this) (NN relationship)) (VP (MD would) (VP (VB be) (VP (VBN mediated) (PP (IN by) (NP (NN lactose) (NN consumption))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN C/T-13910) (NN lactasevariant)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN genotyped) (PP (IN in) (NP (NP (NP (CD 630) (NNS men)) (PP (IN with) (NP (NN drug2)))) (CC and) (NP (CD 873) (JJ matched) (NN control) (NNS participants))))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (DT The) (NN -13910C>T) (NN polymorphism)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (ADVP (JJ upstream) (PP (IN from) (NP (DT the) (NN lactase) (-LRB- -LRB-) (NN LCT) (-RRB- -RRB-) (NN gene))))) (, ,) (VP (ADVP (RB strongly)) (VBN associated) (PP (IN with) (NP (NP (NN drug2)) (PRN (-LRB- -LRB-) (NP (NN LP)) (-RRB- -RRB-)))) (ADVP (FW in) (FW Europeans))) (, ,)) (VP (VBZ is) (VP (VBG emerging) (PP (IN as) (NP (NP (DT a) (JJ new) (NN candidate)) (PP (IN for) (NP (NN drug3)))))))) (. .)))
(S1 (S (S (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (NNS haplotypes)) (PP (IN at) (NP (DT another)))) (VP (VBP block) (VP (VBN tagged) (PP (IN by) (NP (NP (NN drug1)) (VP (VBN associated) (PP (IN with) (NP (NP (JJ prevalent) (NN drug2)) (PRN (-LRB- -LRB-) (NP (NP (CD b=0.239)) (, ,) (NP (NN p=) (CD 2.05) (NN *) (CD 10) (-LRB- -LRB-) (CD -4) (-RRB- -RRB-))) (-RRB- -RRB-)))))))))) (, ,) (CC but) (S (ADVP (RB remarkably)) (NP (DT these)) (VP (VBP are) (ADVP (RB inversely)) (VP (VBN associated) (PP (IN with) (NP (NN disease) (NN severity))) (PRN (-LRB- -LRB-) (NP (CD b=-0.196)) (, ,) (NP (CD p=0.003)) (-RRB- -RRB-)))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN presence)) (PP (IN of) (NP (NP (CD four) (JJ common) (NN oxytocin) (NN receptor) (NN gene) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4))) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN evaluated) (PP (IN in) (NP (NP (NP (QP (CD one) (CD hundred)) (NNS women)) (PP (IN with) (NP (NN drug5)))) (CC and) (NP (NP (QP (CD one) (CD hundred)) (JJ healthy) (NNS women)) (VP (VBG using) (NP (NP (NN restriction) (NN fragment) (NN length) (NN polymorphism)) (VP (VBG genotyping)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN haplotype) (NN analysis))) (, ,) (NP (NP (DT the) (NN haplotype) (NN combination)) (PP (IN of) (NP (NP (NN drug1) (NN A) (NN allele)) (, ,) (NP (NN drug2) (NN C) (NN allele)) (CC and) (NP (NN drug3) (NN G) (NN allele))))) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB be) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NP (DT an) (VBN increased) (NN risk)) (PP (IN of) (NP (NN drug4))))) (PRN (-LRB- -LRB-) (NP (CD OR=3.2) (NN -LSB-CI) (CD 1.04-9.8) (-RRB- -RSB-)) (, ,) (NP (CD p=0.043)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (PP (IN With) (NN respect) (TO to) (NP (NN OXTR) (NN drug1))) (, ,) (NP (NP (NNS mothers)) (PP (IN with) (NP (DT the) (NN GG) (NN genotype)))) (VP (VBD showed) (NP (JJR greater) (NN drug2)) (PP (IN across) (NP (NP (JJ varying) (NNS levels)) (PP (IN of) (NP (JJ interparental) (NN conflict))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NN aim)) (PP (IN of) (NP (DT this) (NN study)))) (VP (VBD was) (S (VP (TO to) (VP (VB investigate) (SBAR (IN whether) (S (NP (NP (DT a) (NN set)) (PP (IN of) (NP (NP (NP (JJ single) (NN nucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NNS SNPs)) (-RRB- -RRB-))) (PP (IN within) (NP (NP (NP (NP (NN cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NP (NN COX-2)) (, ,) (NP (NN drug1)) (CC and) (NP (NN drug2))) (-RRB- -RRB-))) (CC and) (NP (NP (NN oxytocin) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NP (NN OXTR)) (, ,) (NP (NN drug3)) (CC and) (NP (NN drug4))) (-RRB- -RRB-)))) (NNS genes)))))) (VP (VBD was) (VP (VBN associated) (PP (IN with) (NP (NP (NN drug5)) (, ,) (NP (NN response)) (CC or) (NP (NN remission))))))))))))) (. .)))
(S1 (S (S (PP (IN For) (NP (DT this) (NN purpose))) (, ,) (NP (NP (NP (NP (CD two) (JJ single) (NN nucleotide) (NNS polymorphisms)) (PRN (-LRB- -LRB-) (NP (NNS SNPs)) (-RRB- -RRB-))) (, ,) (NP (NP (NP (NN 6930G>A)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (-RRB- -RRB-))) (CC and) (NP (NP (NN 9073G>A)) (PRN (-LRB- -LRB-) (NP (NN drug2)) (-RRB- -RRB-)))) (, ,)) (PP (IN within) (NP (NP (DT the) (NN oxytocin) (NN receptor) (NN gene)) (PRN (-LRB- -LRB-) (NP (NN OXTR)) (-RRB- -RRB-)))) (, ,)) (VP (VBD were) (VP (VBN studied) (PP (IN in) (NP (NP (DT a) (NN cohort)) (PP (IN of) (NP (NP (NP (CD 185) (NNS patients)) (PP (IN with) (NP (NP (NP (JJ major) (NN drug3)) (PRN (-LRB- -LRB-) (NP (CD 50.3) (NN %)) (-RRB- -RRB-))) (CC or) (NP (NN drug4) (CD I) (CC or) (CD II) (NNS disorders)))) (PRN (-LRB- -LRB-) (NP (CD 49.7) (NN %)) (-RRB- -RRB-))) (CC and) (NP (CD 192) (VBN matched) (JJ healthy) (NNS controls))))))))) (. .)))
(S1 (S (S (NP (NP (DT A) (JJ positive) (NN association)) (PP (IN between) (NP (DT the) (NN GG) (NN genotype))) (PP (IN of) (NP (NP (NP (NN drug1) (NN SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN 6930G>A)) (CC or) (NP (NN 9073G>A))) (-RRB- -RRB-))) (CC and) (NP (NN unipolar) (NN drug2))))) (VP (VBD was) (VP (VBN demonstrated)))) (. .)))
(S1 (S (S (PP (IN For) (NP (NN drug1))) (, ,) (NP (NP (NN overtransmission)) (PP (IN of) (NP (DT the) (NN G) (NN allele))) (PP (TO to) (NP (NP (NNS probands)) (PP (IN with) (NP (NN drug2) (NN disorder)))))) (VP (VBD was) (VP (VBN found) (SBAR (WHNP (WDT which)) (S (VP (VBZ contrasts) (PP (IN with) (NP (NP (DT the) (NN overtransmission)) (PP (IN of) (NP (NP (DT A)) (VP (ADVP (RB previously)) (VBN reported) (PP (IN in) (NP (DT the) (NN Chinese) (NN Han) (NN sample)))))))))))))) (. .)))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NP (DT The) (JJ family-based) (NN association) (NN test)) (PRN (-LRB- -LRB-) (NP (NN FBAT)) (-RRB- -RRB-))) (VP (VBD revealed) (NP (NP (DT a) (JJ significant) (JJ genetic) (NN association)) (PP (IN between) (NP (NP (NN drug3)) (CC and) (NP (NP (NP (CD two)) (PP (IN of) (NP (NP (DT the) (NNS SNPs)) (VP (VBN tested))))) (PRN (-LRB- -LRB-) (NP (NN drug1) (NN A)) (: :) (NP (ADJP (NN Z) (JJ =)) (CD 2.287)) (, ,) (NP (NP (NN p)) (ADJP (JJ =) (NP (CD .0222) (: ;) (CD drug2) (NN A)))) (: :) (NP (ADJP (NN Z) (JJ =)) (CD 2.573)) (, ,) (NP (NN p) (JJ =) (CD .0101)) (-RRB- -RRB-)))))))) (. .))))
(S1 (S (S (SBAR (WHADVP (WRB When)) (S (NP (NNS haplotypes)) (VP (VBD were) (VP (VBN constructed) (PP (IN with) (NP (QP (CD two) (, ,) (CD three) (, ,) (CC and) (CD four)) (NNS markers))))))) (, ,) (NP (DT the) (JJ haplotype-specific) (NN FBAT)) (VP (VBD revealed) (SBAR (IN that) (S (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NP (NNS haplotypes)) (, ,) (NP (NP (RB particularly) (DT those)) (VP (VBG involving) (NP (NN drug1)))) (, ,)))) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN associated) (PP (IN with) (NP (NN drug2))))))))) (. .)))
(S1 (S (NP (NP (NNS CONCLUSIONS)) (: :) (S (NP (PRP$ Our) (NN meta-analysis)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (DT the) (NN G) (NN allele)) (PP (IN of) (NP (NN drug1) (NN polymorphism)))) (VP (MD might) (VP (VB be) (NP (NP (DT a) (JJ potential) (NN risk) (NN factor)) (PP (IN for) (NP (NN drug2)))) (, ,) (PP (ADVP (RB especially)) (IN in) (NP (NN whitepopulations))))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ real-time) (NN polymerase) (NN chain) (NN reaction)) (PRN (-LRB- -LRB-) (NP (NN RT-PCR)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB analyze) (NP (NP (NP (CD 4) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NP (NN drug1) (NN A/G)) (, ,) (NP (NN drug2) (NN A/G)) (, ,) (NP (NN drug3) (NN A/G)) (, ,) (NP (NN drug4) (NN C/G))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (CD 291) (NN drug5) (NNS patients)) (CC and) (NP (CD 247) (NNS controls))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Analysis)) (PP (IN of) (NP (CD 4) (NNS SNPs)))) (VP (VBD revealed) (NP (NP (DT a) (JJ significant) (NN difference)) (PP (IN in) (NP (DT the) (NN genotype) (NN distribution))) (PP (PP (IN for) (NP (NP (NP (NN drug1)) (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (PP (IN between) (NP (NP (NN drug5) (NNS patients)) (CC and) (NP (NP (NNS controls)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (NN 0.041)) (, ,) (NP (NN p) (JJ =) (CD 0.005)) (, ,) (S (NP (NN p)) (VP (JJ =) (NP (CD 0.023)) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))))))) (CC but) (PP (RB not) (IN for) (NP (NP (NN drug4)) (PRN (-LRB- -LRB-) (NP (NN p) (JJ =) (CD 0.211)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NP (JJ Minor) (NNS alleles)) (PP (IN in) (NP (NP (CD three) (JJ correlated) (NN ht) (NNS SNPs)) (PRN (-LRB- -LRB-) (NP (NN drug1)) (, ,) (NP (, ,) (NP (NN drug2)) (, ,) (CC and) (NP (NN drug3))) (: ;) (NP (NN r) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-) (CD >0.6)) (-RRB- -RRB-))))) (VP (VBD were) (VP (VBN associated) (PP (IN with) (NP (NP (VBN increased) (NN risk)) (PP (IN for) (NP (NN drug4)))))))) (. .)))
